Investors

AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap

ADD Lonsamhet Vit

The share

Chart Bar

Financial reports and presentations

Calendar

Humans

Corporate governance

  • Good organic growth and strong earnings performance

    Margin improvements remain the highest priority, and during the quarter, profitability was clearly strengthened in both business areas. The margin improvements are mainly driven by ongoing efficiency initiatives, a continuous shift in the product portfolio towards more advanced, as well as active pricing efforts. Organic growth in the quarter was driven by positive developments in both business areas. Our acquisitions have developed well, with strong growth, improved margins, and significantly improved cash flows. Profit for the period improved by 228 percent in the quarter.

    comments by the ceo
    Fredrik Dalborg Addlife Q3 2025 Sq

Listen to our latest presentation

 

AddLife creates value

The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.

AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.

ADD Lonsamhet Vit

AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.

ADD Ansvar Vit

AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.

ADD Engagemang Vit

Target fulfilment 2024

Earnings growth

Profitability

Dividend

Contact us!

The investor pages contain all published financial information to facilitate investment decisions.

We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.

Contact: [email protected]

IR- and press contacts

Fredrik Dalborg (2)

Fredrik Dalborg

CEO

[email protected]

Christina Rubenhag

Christina Rubenhag

CFO

[email protected]

Julie Oleary

Julie O'Leary

Investor Relations Manager

[email protected]

Subscribe